{
    "clinical_study": {
        "@rank": "18501", 
        "arm_group": {
            "arm_group_label": "AZD6094 600 mg daily continuously", 
            "arm_group_type": "Experimental", 
            "description": "All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously."
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, single-arm, multicentre, global, Phase II, study designed to evaluate\n      the efficacy and safety of AZD6094 in patients with PRCC who are treatment na\u00efve or\n      previously treated."
        }, 
        "brief_title": "A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Papillary Renal Cell Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, single-arm, multicentre, global, Phase II, study designed to evaluate\n      the efficacy and safety of AZD6094 in patients with PRCC who are treatment na\u00efve or\n      previously treated.\n\n      An independent central pathology review of tumour samples will be used to confirm the\n      diagnosis of PRCC of all patients enrolling.  However, locally available pathology results\n      confirming PRCC will be allowed for timely study entry.\n\n      All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD).\n      Treatment will be given continuously."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          -  Provision of informed consent prior to any study specific procedures, sampling and\n             analyses.\n\n          -  Histologically confirmed papillary renal cell cancer, which is locally advanced\n\n          -  Availability of an archival tumor sample or a pre-treatment fresh tumor sample for\n             confirmation of PRCC by a central laboratory and other biomarker\n\n          -  Treatment na\u00efve or previously treated PRCC.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n          -  At least one lesion, not previously irradiated, and not chosen for a biopsy if\n             performed during the screening period that can be accurately measured at baseline and\n             which is suitable for accurate repeated measurements.\n\n          -  Adequate hematological function defined as:\n\n               1. (ANC) \u22651500/\u03bcL\n\n               2. (Hgb) \u22659 g/dL\n\n               3. Platelets \u2265100,000/\u03bcL\n\n          -  Adequate liver function defined as:\n\n               1. (ALT) and (AST) \u22642.5 xthe upper limit of normal (ULN)\n\n               2. Total bilirubin \u22641.5 x ULN\n\n          -  Adequate renal function defined as glomerular filtration rate (GFR) \u2265 40 mL/min,\n\n          -  Adequate coagulation parameters, defined as International Normalisation Ratio(INR)\n             <1.5 x ULN or activated partial thromboplastin time (aPTT) <1.5 x ULN.\n\n          -  Patients with known tumor thrombus or deep vein thrombosis (DVT) are eligible if\n             stable on low molecular weight heparin (LMWH) for \u22654 weeks.\n\n          -  Females should be using adequate contraceptive measures should notbe breast feeding,\n             and must have a negative pregnancy test prior to start of dosing ifof childbearing\n             potential or must have evidence of non-childbearing potential\n\n          -  Male patients should be willing to use barrier contraception, i.e. condoms.\n\n          -  Ability to swallow and retain oral medications.\n\n          -  Predicted life expectancy \u226512 weeks.\n\n          -  Aged at least 18 years.\n\n          -  Willingness and ability to comply with study and follow-up procedures.\n\n          -  Ability to understand the nature of this study and give written informed consent.\n\n        Exclusion criteria\n\n          -  Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational\n             agents <21 days of the first dose of study treatment. Most recent targeted therapy\n             <14 days of the first dose of study treatment.\n\n          -  Unresolved toxicities from any prior therapy greater than Common Terminology Criteria\n             for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment with the\n             exception of alopecia.\n\n          -  Prior or current treatment with a cMet inhibitor\n\n          -  Strong inducers or inhibitors of CYP3A4 or strong inhibitors of CYP1A2 within 2 weeks\n             before the first dose of study treatment (3 weeks for St John's Wort)\n\n          -  Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89)\n             administered \u226428 days or limited field radiation for palliation \u22647 days prior to\n             starting study drug or has not recovered from side effects of such therapy\n\n          -  Major surgical procedures \u226428 days of beginning study drug or minor surgical\n             procedures \u22647 days. No waiting is required following port-a-cath placement.\n\n          -  Previously untreated brain metastases.\n\n          -  Current leptomeningeal metastases or spinal cord compression due to disease.\n\n          -  Acute or chronic liver or pancreatic disease.\n\n          -  Uncontrolled diabetes mellitus.\n\n          -  Gastrointestinal disease or other condition that will interfere significantly with\n             the absorption, distribution, metabolism, or excretion of oral therapy\n\n          -  Any of the following cardiac diseases currently or within the last 6 months:\n\n               1. Unstable angina pectoris\n\n               2. Congestive heart failure (New York Heart Association [NYHA] \u2265 Grade 2\n\n               3. Acute myocardial infarction\n\n               4. Stroke or transient ischemic attack\n\n          -  Inadequately controlled hypertension (i.e., systolic blood pressure [SBP] >160 mmHg\n             or diastolic blood pressure (DBP) >100 mmHg) (patients with values above these levels\n             must have their blood pressure (BP) controlled with medication prior to starting\n             treatment).\n\n          -  Mean resting correct QT interval (QTc) >470 msec obtained from triplicate ECGs.\n\n          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting\n             electrocardiograms (ECGs), e.g. complete left bundle branch block, third degree heart\n             block, second degree heart block, PR interval >250 msec.\n\n          -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic events\n             such as heart failure, hypokalaemia, congenital or familial long QT syndrome or\n             unexplained sudden death under 40 years of age or any concomitant medications known\n             to prolong QT interval.\n\n          -  Currently receiving treatment with therapeutic doses of warfarin sodium. Low\n             molecular weight heparin (LMWH) is allowed.\n\n          -  Serious active infection at the time of treatment, or another serious underlying\n             medical condition that would impair the ability of the patient to receive protocol\n             treatment.\n\n          -  Known diagnosis of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.\n\n          -  Presence of other active cancers, or history of treatment for invasive cancer\n             \u22645years. Patients with Stage I cancer who have received definitive local treatment at\n             least 3 years previously, and are considered unlikely to recur are eligible. All\n             patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible,\n             as are patients with history of non-melanoma skin cancer.\n\n          -  Psychological, familial, sociological, or geographical conditions that do not permit\n             compliance with the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127710", 
            "org_study_id": "D5082C00002"
        }, 
        "intervention": {
            "arm_group_label": "AZD6094 600 mg daily continuously", 
            "description": "AZD6094 is a potent and selective small molecule cMet kinase inhibitor.", 
            "intervention_name": "AZD6094", 
            "intervention_type": "Drug", 
            "other_name": "HMPL - 504"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Papillary Renal Cell Cancer", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "W1G 6AD"
                }, 
                "name": "Sarah Cannon Research Institute United Kingdom"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Bernadette Weidman", 
            "phone": "302-886-5131"
        }, 
        "overall_contact_backup": {
            "last_name": "Joanne Meredith", 
            "phone": "(813) 920-7423"
        }, 
        "overall_official": {
            "affiliation": "Sarah Cannon Research Institute United Kingdom", 
            "last_name": "Henrik-Tobias Arkenau, MD,PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The response rate is defined as the number (%) of subjects with at least one visit response of complete or partial response that is confirmed at least 4 weeks later.", 
            "measure": "Assess the antitumor activity of AZD6094 as measured by Overall Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Up to 7 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127710"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression-free survival is defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the subject withdraws from randomised therapy or receives another anti-cancer therapy prior to progression.", 
                "measure": "Assess progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 months"
            }, 
            {
                "description": "Safety profiles will be assessed in terms of AEs and laboratory data, vital signs and ECGs that will be collected for all patients.", 
                "measure": "Assess the safety and tolerability of AZD 6094", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 7 months"
            }, 
            {
                "description": "Characterise the pharmacokinetics (PK) of AZD6094 and the major metabolites M2 and M3 following administration to steady state after multiple dosing when given orally.", 
                "measure": "Pharmacokinetics (PK) of AZD6094 and major metabolites M2 and M3 for AUC, AUC(0-24), AUC(0-t), AUCss, Cmax, Css max, and Css min", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 8 and 15, Cycle 2 Day 1, Cycle 3, Day 1, and Cycle 4, Day 1"
            }, 
            {
                "description": "Change in Target Lesion is percentage change from baseline in tumor size at 12 weeks. This is based on RECIST target lesion measurements taken at baseline and at week 12. Target lesions are measureable tumour lesions.", 
                "measure": "Assess change in target lesion tumor size from baseline", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 months"
            }, 
            {
                "description": "Duration of Response is defined as the time from the date of first documented response until the date of documented progression or any cause death. In the case where a subject does not progress following response, the duration of response will be the same as the PFS censoring time.", 
                "measure": "Assess duration of response according to RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 months"
            }, 
            {
                "description": "Overall Survival (OS) - Overall survival is defined as the time from the date of randomization until death due to any cause.", 
                "measure": "Assess duration of overall survival according to RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 7 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "SCRI Development Innovations, LLC", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}